ecancermedicalscience

Clinical Study

Unravelling Eribulin’s role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings

28 Nov 2024
Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, Pooja Gupta, Bal Krishna Mishra, Arpita Singh, Arvind Upadhyay, Amit Kumar, Mayank Tripathi, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Neha Singh, Shreya Shukla, Satyendra Narayan Singh, Lincoln Pujari, Prashanth Giridhar, Ankita Rungta Kapoor, Yash Jain, Manikandan Venkatachalam, Somnath Dey, Kunal Ranjan Vinayak

Background: Metastatic breast cancer (MBC) patients have numerous options for treatment. However, it is essential to consider treatments with favorable toxicity profiles and convenient modes of administration. Eribulin has shown effectiveness in aggressive MBC, but there is a lack of sufficient real-world data specific to Indian patients.

Patients and methods: We conducted a retrospective audit of patients with MBC who received intravenous Eribulin between 2019 and 2023 at a dosage of 1.4 mg/m2 on days 1 and 8 every 3 weeks. The median Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

Results: During the specified time, 107 consecutive patients with MBC received Eribulin treatment. The median age was 52 years (range, 28–75 years) with 3 patients with male breast cancer. The median number of prior chemotherapy lines and involved sites were 3 (range, 2–5) and 3 (range, 1–6), respectively. Visceral involvement was present in 84 (78.5%) patients. A median of 3 cycles of Eribulin (range, 1–11) was administered. Eribulin resulted in partial responses in 49 (45.8%) patients, stable disease in 11 (10.3%) patients and progressive disease in 47 (43.9%) patients. The median PFS was 4.0 months (95% CI: 3.4–4.6), and the median OS was 10.0 months (95% CI: 8.3–11.7). For patients with triple-negative breast cancer (TNBC), the median OS was 8 months (95% CI: 5.6–10.4), whereas non-TNBC patients had a median OS of 11 months (95% CI: 9.1–12.8) (hazard ratio, 1.9, 95% CI: 1.2–3.1, p = 0.002). Eribulin was well-tolerated, with dose reduction was needed in 9 (8.4%) of the patients in the overall cohort.

Conclusion: Eribulin is a viable and safe option for treating heavily pre-treated MBC in real-world settings. The study found comparable efficacy in both TNBC and non-TNBC patients.

Related Articles

Arunah Chandran, Ishu Kataria, Kunal Oswal, Rita Isaac, Meritxell Mallafré-Larrosa, Sathishrajaa Palaniraja, Rajaraman Swaminathan, Rohit Rebello, Nandimandalam Venkata Vani, Bindhya Vijayan, Moni Kuriakose, Arnie Purushotham, Rengaswamy Sankaranarayanan, Jerard Selvam, Richard Sullivan, Partha Basu
Chalothorn Wannaphut, Phuuwadith Wattanachayakul, Sakditad Saowapa, Ben Ponvilawan, Manasawee Tanariyakul, Jakrin Kewcharoen, Pitchaporn Yingchoncharoen, Thanathip Suenghataiphorn, Noppawit Aiumtrakul, Jared Acoba
Fatuma Affey, Dabo Galgalo Halake, Grace Muira Wainaina, Hussein Ali Osman, James G Ndukui, Houda Abdourahman, Omar Abdihamid
José Richard Tenazoa-Villalobos, Edgar Fermín Yan-Quiroz, Augusto Ordoñez-Chinguel, Sofia Leonor Prado-Cucho, Adesman Isac Miranda-Narro, Vladimir Villoslada-Terrones
Tinashe Adrian Mazhindu, Ntokozo Ndlovu, Margaret Borok, Vincent Aketch Nyangwara, Pageneck Chikondowa, Marie Hidjo Madeleine, Collen Masimirembwa, Onesai Chihaka, Edith Matsikidze, Charley Jang, Kevin Grimes